scholarly journals The role of molecular breast imaging in predicting complete tumor response to treatment and residual tumor extent following neoadjuvant therapy

2018 ◽  
Author(s):  
Susanna Nuvoli ◽  
Sarah Galassi ◽  
Ilaria Gelo ◽  
Gaia Rocchitta ◽  
Alessandro� Fancellu ◽  
...  
Keyword(s):  
Neoadjuvant Therapy ◽  
Breast Imaging ◽  
Tumor Response ◽  
Residual Tumor ◽  
Response To Treatment ◽  
Molecular Breast Imaging ◽  
Tumor Extent ◽  
Complete Tumor

scholarly journals A New Role of Vemurafenib as a Neoadjuvant Treatment of Axillary and Brain Melanoma Metastases

2013 ◽  
Vol 2013 ◽  
pp. 1-3 ◽  
Author(s):  
Idit Melnik ◽  
Michal Lotem ◽  
Boris Yoffe
Keyword(s):  
Lymph Node ◽  
Brain Metastases ◽  
Metastatic Melanoma ◽  
Neoadjuvant Therapy ◽  
Tumor Necrosis ◽  
Neoadjuvant Treatment ◽  
Melanoma Metastases ◽  
Excisional Surgery ◽  
Complete Tumor

Vemurafenib is approved by the FDA for the management of unresectable or metastatic melanoma. However, its role as a neoadjuvant therapy has not been determined. We present the first documented case in which vemurafenib induced complete tumor necrosis of both lymph node and brain metastases within one month or less, an outcome that indicated that the patient was a good candidate for excisional surgery.

scholarly journals The Use of Molecular Breast Imaging to Assess Response in Women Undergoing Neoadjuvant Therapy for Breast Cancer

2012 ◽  
Vol 37 (4) ◽  
pp. 344-350 ◽  
Author(s):  
Dietlind L. Wahner-Roedler ◽  
Judy C. Boughey ◽  
Carrie B. Hruska ◽  
Beiyun Chen ◽  
Deborah J. Rhodes ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Therapy ◽  
Breast Imaging ◽  
Molecular Breast Imaging

scholarly journals The role of the neoadjuvant approach in the treatment of primary operable HER2 positive breast cancer

2020 ◽  
Vol 10 (2) ◽  
pp. 45-52
Author(s):  
M. A. Frolova ◽  
Е. V. Glazkova ◽  
A. V. Petrovsky ◽  
О. V. Krokhina ◽  
M. В. Stenina ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Response ◽  
Residual Tumor ◽  
Response To Treatment ◽  
Comprehensive Treatment ◽  
Her2 Positive ◽  
Ki 67 ◽  
Her2 Positive Breast Cancer ◽  
Neoadjuvant Systemic Therapy ◽  
Positive Breast Cancer

Neoadjuvant systemic therapy is an essential component of the comprehensive treatment of primary operable HER2‑positive breast cancer. Therefore, it is extremely important to search for treatment efficacy predictors and optimal system for assessing tumor response to treatment. The study analyzed factors predicting pathological complete response (pCR) in patients with luminal and non‑luminal HER2‑positive tumor subtypes. The morphological assessment of the tumor response to treatment was carried out using the RCB system; additional characteristics of the residual tumor were studied as well. It was shown that a comprehensive assessment involving the use of the RCB system and determination of the Ki ‑ 67 level helps to divide patients into prognostic groups and individualize the adjuvant therapy plan.

scholarly journals Predicting Tumor Response to Radiotherapy Based on Estimation of Non-Treatment Parameters

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Yutian Huang ◽  
Allison Lewis
Keyword(s):  
Treatment Efficacy ◽  
Tumor Response ◽  
Synthetic Data ◽  
Response To Treatment ◽  
Tumor Characteristics ◽  
Patient Response ◽  
Differential Equation Models ◽  
Tumor Remission ◽  
Parameter Distributions ◽  
Complete Tumor

Though clinicians can now collect detailed information about a variety of tumor characteristics as a tumor evolves, it remains difficult to predict the efficacy of a given treatment prior to administration. Additionally, the process of data collection may be invasive and expensive. Thus, the creation of a framework for predicting patient response to treatment using only information collected prior to the start of treatment could be invaluable. In this study, we employ ordinary differential equation models for tumor growth and utilize synthetic data from a cellular automaton model for calibration. We investigate which parameters have the most influence upon treatment efficacy by comparing parameter distributions associated with treatment outcomes. Additionally, we develop a framework for estimating the probability of observing complete tumor remission following a simulated radiotherapy regimen based only on a patient’s non-treatment parameters, so that treatment efficacy could be predicted prior to administration.

Assessment of Residual Disease With Molecular Breast Imaging in Patients Undergoing Neoadjuvant Therapy: Association With Molecular Subtypes

2016 ◽  
Vol 16 (5) ◽  
pp. 389-395 ◽  
Author(s):  
Tehillah S. Menes ◽  
Orit Golan ◽  
Gilead Vainer ◽  
Hedva Lerman ◽  
Schlomo Schneebaum ◽  
...  
Keyword(s):  
Neoadjuvant Therapy ◽  
Breast Imaging ◽  
Molecular Subtypes ◽  
Residual Disease ◽  
Molecular Breast Imaging

scholarly journals Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement

2021 ◽  
pp. 030089162110626
Author(s):  
Elena Guerini-Rocco ◽  
Gerardo Botti ◽  
Maria Pia Foschini ◽  
Caterina Marchiò ◽  
Mauro Giuseppe Mastropasqua ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Therapy ◽  
Early Breast Cancer ◽  
Tumor Response ◽  
Pathologic Complete Response ◽  
Complete Response ◽  
Response To Treatment ◽  
Lymph Node Status ◽  
Prognostic Information ◽  
Consensus Statements

Pathologic evaluation of early breast cancer after neoadjuvant therapy is essential to provide prognostic information based on tumor response to treatment (pathologic complete response [pCR] or non-pCR) and to inform therapy decisions after surgery. To harmonize the pathologist’s handling of surgical specimens after neoadjuvant therapy, a panel of experts in breast cancer convened to developed a consensus on six main topics: (1) definition of pCR, (2) required clinical information, (3) gross examination and sampling, (4) microscopic examination, (5) evaluation of lymph node status, and (6) staging of residual breast tumor. The resulting consensus statements reported in this document highlight the role of an accurate evaluation of tumor response and define the minimum requirements to standardize the assessment of breast cancer specimens after neoadjuvant therapy.

Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?

1985 ◽  
Vol 3 (7) ◽  
pp. 1013-1021 ◽  
Author(s):  
I F Tannock
Keyword(s):  
Prostatic Carcinoma ◽  
Progressive Disease ◽  
Tumor Response ◽  
Metastatic Carcinoma ◽  
Cytotoxic Chemotherapy ◽  
Response To Treatment ◽  
Carcinoma Of The Prostate ◽  
Standard Management

Most patients with metastatic carcinoma of the prostate have osteoblastic bone metastases and nonmeasurable pelvic disease. These features cause patients to be at high risk for myelosuppression after cytotoxic chemotherapy and make it difficult to evaluate response to treatment. A critical review of larger trials that have sought to assess the role of chemotherapy in treatment of carcinoma of the prostate leads to the following conclusions: (1) Although the aim of treatment is palliation, most trials have tried to evaluate tumor response rather than the more appropriate endpoints of quality and quantity of survival for all treated patients. (2) Criteria that have been used for tumor response are variable and contain large inherent errors; most patients who are labeled as "responders" are described as being "objectively stable," but this category may be a manifestation of slowly progressive disease rather than a response to treatment. (3) There is no evidence that chemotherapy causes a meaningful prolongation of survival. (4) Chemotherapy adds considerable toxicity, and reported trials have not adequately assessed its overall impact on quality of life. Because of these factors there is little evidence that chemotherapy provides palliation for patients with prostatic carcinoma, and it should not be regarded as part of standard management. Selected patients who are symptomatic and no longer responding to hormones may be considered for trials of chemotherapy. Future trials should randomize patients to chemotherapy or supportive care, with assessment of quality and quantity of survival for all randomized patients by an observer who is unaware of the treatment.

scholarly journals Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy

Cancers ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 1511 ◽  
Author(s):  
Ella F. Jones ◽  
Deep K. Hathi ◽  
Rita Freimanis ◽  
Rita A. Mukhtar ◽  
A. Jo Chien ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Therapy ◽  
Breast Imaging ◽  
Imaging Modality ◽  
Neoadjuvant Treatment ◽  
Specific Treatment ◽  
Response To Treatment ◽  
Breast Cancers ◽  
Treatment Approaches ◽  
Imaging Markers

In recent years, neoadjuvant treatment trials have shown that breast cancer subtypes identified on the basis of genomic and/or molecular signatures exhibit different response rates and recurrence outcomes, with the implication that subtype-specific treatment approaches are needed. Estrogen receptor-positive (ER+) breast cancers present a unique set of challenges for determining optimal neoadjuvant treatment approaches. There is increased recognition that not all ER+ breast cancers benefit from chemotherapy, and that there may be a subset of ER+ breast cancers that can be treated effectively using endocrine therapies alone. With this uncertainty, there is a need to improve the assessment and to optimize the treatment of ER+ breast cancers. While pathology-based markers offer a snapshot of tumor response to neoadjuvant therapy, non-invasive imaging of the ER disease in response to treatment would provide broader insights into tumor heterogeneity, ER biology, and the timing of surrogate endpoint measurements. In this review, we provide an overview of the current landscape of breast imaging in neoadjuvant studies and highlight the technological advances in each imaging modality. We then further examine some potential imaging markers for neoadjuvant treatment response in ER+ breast cancers.

Sign in / Sign up

Export Citation Format

Share Document